A Phase 1 Study Evaluating Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS67E Given as Monotherapy in Subjects With Refractory or Relapsed Lymphoid Malignancies

Trial Profile

A Phase 1 Study Evaluating Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS67E Given as Monotherapy in Subjects With Refractory or Relapsed Lymphoid Malignancies

Suspended
Phase of Trial: Phase I

Latest Information Update: 06 Dec 2017

At a glance

  • Drugs AGS 67E (Primary)
  • Indications Chronic lymphocytic leukaemia; Hairy cell leukaemia; Lymphoid leukaemia; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors Agensys
  • Most Recent Events

    • 30 Nov 2017 Status changed from recruiting to suspended.
    • 02 May 2017 Planned End Date changed from 1 Apr 2017 to 30 Jun 2019.
    • 02 May 2017 Planned primary completion date changed from 1 Apr 2017 to 30 Jun 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top